News & Updates

A retrospective analysis has shown that increasing the dose of subcutaneous infliximab (CT-P13 SC) from 120 to 240 mg Q2W in patients with inflammatory bowel disease who initially responded but subsequently lost response leads to improved clinical efficacy over an extended period.

Addition of sintilimab to pemetrexed and platinum-based chemotherapy maintained or improved health-related quality of life (HRQoL) and symptoms compared with chemotherapy alone in first-line (1L) treatment of locally advanced or metastatic non-squamous non-small-cell lung cancer (NSCLC), according to a prespecified exploratory analysis of the phase III ORIENT-11 trial.

Treatment with colchicine appears to lower the risk of stroke and major adverse cardiovascular events (MACE) when used for longer duration, according to a study presented at ISC 2025. This beneficial effect, however, is not observed among patients with shorter follow-up duration.

The addition of intravenous thrombolysis (IVT) to endovascular thrombectomy (EVT) provides significant clinical benefits to patients who experienced acute ischaemic stroke (AIS) caused by large vessel occlusion (LVO) with large ischaemic infarcts (LII), as shown by the findings of a meta-analysis presented at the recent ISC 2025.